# Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

> **NCT02084199** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 24 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** GLPG0634

## Key facts

- **NCT ID:** NCT02084199
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02084199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02084199, "Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02084199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*